Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported an automatic share disposition related to taxes. On the reported date, 2,010 shares of Common Stock were withheld at a price of $17.93 per share to satisfy tax obligations. After this tax-withholding disposition, he held 194,009 shares of Common Stock directly.
Omada Health, Inc. President Shao Wei-Li reported a tax-related share disposition. On the transaction date, 1,843 shares of Common Stock were withheld at a price of $17.93 per share to cover tax obligations. After this non-market transaction, Shao Wei-Li directly held 320,827 shares.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported a tax-related share disposition. On June 1, 2026, 4,493 shares of Common Stock were withheld at $18.38 per share to satisfy tax obligations, classified as a tax-withholding disposition rather than an open-market sale.
After this transaction, Cook directly holds 196,019 shares of Omada Health common stock. The filing shows no option exercises or open-market purchases or sales, indicating this was a routine compensation-related tax event.
Omada Health, Inc. Chief Accounting Officer Craig Gracey reported a small tax-related share transaction. On June 1, 2026, 385 shares of Common Stock were disposed of as a tax-withholding disposition, using shares valued at $18.38 each to cover tax obligations. After this non-market event, Gracey directly holds 16,085 Common Stock shares.
Omada Health, Inc. President Shao Wei-Li reported a tax-related share disposition. On June 1, 2026, 6,180 shares of common stock were withheld at $18.38 per share to cover tax obligations. After this non-market transaction, Shao Wei-Li directly holds 322,670 shares of Omada Health common stock.
Omada Health, Inc. CEO Sean P. Duffy reported a routine tax-related share withholding and updated his holdings. A total of 9,884 shares of common stock were disposed of at $18.38 per share as a tax-withholding disposition, leaving him with 440,693 shares held directly. He also has 851,659 shares reported as held indirectly through family trusts for the benefit of family members, for which he disclaims beneficial ownership except for his pecuniary interest.
Omada Health, Inc. reporting persons led by Andreessen Horowitz files an amendment to a Schedule 13G/A disclosing beneficial ownership stakes as of March 31, 2026. The filing lists aggregate holdings for affiliated entities and individuals, including 2,105,300 shares held by Andreessen Horowitz Fund IV, 201,984 shares held by AH Parallel Fund IV, and individual indirect holdings for Marc L. Andreessen and Benjamin A. Horowitz.
The percentages are calculated using 59,240,000 shares outstanding as of March 31, 2026, with reported percentages of 3.6%, 0.3%, 3.9%, and 4.2% for specific reporting persons. Ownership disclosures include descriptions of voting and dispositive powers and entity relationships; the Reporting Persons disclaim status as a "group."
Omada Health, Inc. Schedule 13G shows Divisadero Street Capital Management, LP and related entities and William Zolezzi report shared beneficial ownership of common stock. The filing lists 5,887,715 shares (9.9%) for Divisadero Street Capital Management and William Zolezzi and 4,487,262 shares (7.6%) for Divisadero Street Partners, L.P., with all shared voting and dispositive power recorded as shown.
The statement clarifies these securities are directly owned by advisory clients of Divisadero Street Capital Management, LP, and notes signatures and joint filing exhibits for allocation and control-person identification.
Omada Health, Inc. reported strong first-quarter 2026 growth with a smaller loss. Revenue rose to $78.0 million, up 42% from $55.0 million a year earlier, driven by a 51% increase in average members and higher hardware shipments. Services revenue reached $69.6 million and hardware revenue $8.5 million.
Gross profit increased to $48.7 million and gross margin expanded to 62.4%, helped by efficiency initiatives in Care Team operations and supporting technology. The net loss narrowed to $3.0 million from $9.4 million, while cash and cash equivalents remained high at $211.8 million. Total members reached 1,025,000 as of March 31, 2026.
Omada Health reported strong first-quarter 2026 growth with improving profitability metrics. Revenue reached $78.0 million for the three months ended March 31, 2026, up 42% year over year, while Total Members grew to 1.02 million, a 51% increase, highlighting expanding adoption of its virtual cardiometabolic care platform.
GAAP gross margin improved to 62%, and non-GAAP gross margin to 64%. Net loss narrowed to $3.0 million from $9.4 million a year earlier, and adjusted EBITDA turned positive at $0.9 million versus a $4.2 million loss. Omada ended the quarter with $211.8 million of cash and cash equivalents and raised its full-year 2026 revenue and adjusted EBITDA outlook.